Option 1 - Enterprise Platform Comparison and Decision Focus:
Option 1 - Platform Comparison and Business Decision Focus:
Option 1 - Plain-Language Business Comparison Focus: This 90-minute masterclass answers the question every business professional is asking in 2026: what is actually different about Copilot, ChatGPT and Claude, and which one should I be using for my work? Ray cuts through the marketing language and technical jargon to give business professionals a clear, practical and honestly assessed comparison of all three platforms across the areas that affect real business use every day.
Option 1 - Full-Spectrum Performance Comparison Focus: This 90-minute masterclass gives professionals the most comprehensive, evidence-based comparison of Microsoft Copilot, ChatGPT, Claude and Gemini available in a single live session.
The FDA holds companies responsible for filing new 510(k)s when one change is major enough to impact safety/effectiveness, or when a series of lesser changes finally reach the "tipping point".
The US FDA has announced steps toward a new regulatory policy and framework specifically tailored to promote the development of safe and effective drugs using advanced artificial intelligence / machine learning algorithms by the regulated industry.
It will also consider the European Union's MDR Technical Documentation requirements, and evaluate the documents' differing purposes / goals, as well as the two different device classification schemes. Required and desirable contents will be discussed.
The artificial intelligence technologies granted FDA marketing authorization and cleared by the agency so far are generally called "locked" algorithms that don't continually adapt or learn every time the algorithm is used.
Verification and validation requirements have always been part of the US FDA's GMPs. Yet companies still struggle with the performance of and documentation of Equipmnet, Process, Software, and quality management system validations.
This webinar will provide valuable guidance to regulated companies in development and implementation of formal, defined, documented methods for analysis of product changes and when to file a new 510(k).
This webinar will examine the existing requiements for theUS FDA's DHF - including its derivitive documents, the DMR and DHR, and the identical ISO 13485 7.3 D&DF.
This webinar is designed to provide an overview of the problem of counterfeit drugs and suggest ways to combat it, some that have been employed for years and others that have been developed more recently.
Instrumental liquid chromatography is an analysis are widely used to determine purity, the impurities, and the degradation products of pharmaceuticals.
Learning Management Systems (LMSs) are important tools for assuring and demonstrating that Pharma employees maintain their training, and their GMP compliance, up to date.
Substandard product can exist even if the product itself is manufactured according to quality standards.
If you do any work that will be reported to the US Food and Drug Administration (FDA), Environmental Protection Agency (EPA), or Occupational Safety and Health Administration (OSHA), your work must be done under GLP.
Occupying a critical position in the success or failure of any pharmaceutical product launch, Packaging and Labeling form a bridge between the conception of a product and its realization and distribution.
Assessment of the cause for a non-compliance is a structured series of branching questions.
Job aids, also known as work instructions, are documents that resemble SOPs, but their content, use and training are different than those for SOPs.
This webinar will begin by discussing the eleven PM monitoring and controlling processes that are the foundation of the project management processes.
